NeoGenomics Appoints Warren Stone as President & Chief Operating Officer
NeoGenomics (NASDAQ:NEO) has promoted Warren Stone from Chief Commercial Officer to President & Chief Operating Officer, effective April 1, 2025. Stone, with over 25 years of experience, will oversee lab operations, data solutions division, and enterprise operations while maintaining his commercial responsibilities.
Under Stone's leadership since November 2022, the Clinical division has achieved eight consecutive quarters of double-digit revenue growth. The current Chief Operations Officer, Melody Harris, will depart in May. Beth Eastland, Senior Vice President of Enterprise Sales, will support Stone and manage enterprise sales functions.
This organizational restructuring aligns commercial and operations teams to enhance agility and leverage the company's portfolio. The leadership team aims to accelerate growth and profitability while focusing on patient and provider experience.
NeoGenomics (NASDAQ:NEO) ha promosso Warren Stone da Chief Commercial Officer a Presidente e Chief Operating Officer, con effetto dal 1 aprile 2025. Stone, con oltre 25 anni di esperienza, supervisionerà le operazioni di laboratorio, la divisione delle soluzioni dati e le operazioni aziendali, mantenendo le sue responsabilità commerciali.
Sotto la guida di Stone, dal novembre 2022, la divisione Clinica ha raggiunto otto trimestri consecutivi di crescita dei ricavi a doppia cifra. L'attuale Chief Operations Officer, Melody Harris, lascerà l'azienda a maggio. Beth Eastland, Senior Vice President delle Vendite Aziendali, supporterà Stone e gestirà le funzioni di vendita aziendale.
Questa ristrutturazione organizzativa allinea i team commerciali e operativi per migliorare l'agilità e sfruttare il portafoglio dell'azienda. Il team di leadership mira ad accelerare la crescita e la redditività, concentrandosi sull'esperienza dei pazienti e dei fornitori.
NeoGenomics (NASDAQ:NEO) ha promovido a Warren Stone de Chief Commercial Officer a Presidente y Chief Operating Officer, con efecto a partir del 1 de abril de 2025. Stone, con más de 25 años de experiencia, supervisará las operaciones de laboratorio, la división de soluciones de datos y las operaciones empresariales, manteniendo sus responsabilidades comerciales.
Bajo el liderazgo de Stone desde noviembre de 2022, la división Clínica ha logrado ocho trimestres consecutivos de crecimiento de ingresos de dos dígitos. La actual Chief Operations Officer, Melody Harris, dejará la empresa en mayo. Beth Eastland, Vicepresidenta Senior de Ventas Empresariales, apoyará a Stone y gestionará las funciones de ventas empresariales.
Esta reestructuración organizativa alinea los equipos comerciales y operativos para mejorar la agilidad y aprovechar la cartera de la empresa. El equipo de liderazgo tiene como objetivo acelerar el crecimiento y la rentabilidad mientras se centra en la experiencia del paciente y del proveedor.
NeoGenomics (NASDAQ:NEO)는 Warren Stone을 최고 상업 책임자에서 사장 겸 최고 운영 책임자로 승진시키며, 2025년 4월 1일부터 효력이 발생한다고 발표했습니다. Stone은 25년 이상의 경력을 바탕으로 실험실 운영, 데이터 솔루션 부서 및 기업 운영을 감독하며 상업적 책임도 유지할 것입니다.
Stone의 지도 아래 2022년 11월 이후로 임상 부서는 8분기 연속 두 자릿수 매출 성장을 달성했습니다. 현재 최고 운영 책임자인 Melody Harris는 5월에 퇴사할 예정입니다. 기업 영업 수석 부사장인 Beth Eastland가 Stone을 지원하고 기업 영업 기능을 관리할 것입니다.
이번 조직 재편성은 상업 및 운영 팀을 정렬하여 민첩성을 향상시키고 회사의 포트폴리오를 활용하는 데 목적이 있습니다. 리더십 팀은 환자 및 제공자 경험에 집중하면서 성장과 수익성을 가속화하는 것을 목표로 하고 있습니다.
NeoGenomics (NASDAQ:NEO) a promu Warren Stone de Directeur Commercial à Président et Directeur des Opérations, avec effet au 1er avril 2025. Stone, avec plus de 25 ans d'expérience, supervisera les opérations de laboratoire, la division des solutions de données et les opérations d'entreprise tout en maintenant ses responsabilités commerciales.
Depuis la prise de fonction de Stone en novembre 2022, la division Clinique a réalisé huit trimestres consécutifs de croissance à deux chiffres des revenus. L'actuelle Directrice des Opérations, Melody Harris, quittera l'entreprise en mai. Beth Eastland, Vice-Présidente Senior des Ventes Entreprises, soutiendra Stone et gérera les fonctions de vente aux entreprises.
Cette restructuration organisationnelle aligne les équipes commerciales et opérationnelles pour améliorer l'agilité et tirer parti du portefeuille de l'entreprise. L'équipe de direction vise à accélérer la croissance et la rentabilité tout en se concentrant sur l'expérience des patients et des fournisseurs.
NeoGenomics (NASDAQ:NEO) hat Warren Stone vom Chief Commercial Officer zum Präsidenten und Chief Operating Officer befördert, mit Wirkung zum 1. April 2025. Stone, der über 25 Jahre Erfahrung verfügt, wird die Laboroperationen, die Datenlösungsabteilung und die Unternehmensoperationen überwachen und gleichzeitig seine kommerziellen Verantwortlichkeiten beibehalten.
Unter Stones Führung hat die Klinische Abteilung seit November 2022 acht aufeinanderfolgende Quartale mit zweistelligem Umsatzwachstum erzielt. Die derzeitige Chief Operations Officer, Melody Harris, wird im Mai ausscheiden. Beth Eastland, Senior Vice President für Unternehmensverkäufe, wird Stone unterstützen und die Unternehmensvertriebsfunktionen leiten.
Diese organisatorische Umstrukturierung bringt die kommerziellen und operativen Teams in Einklang, um die Agilität zu verbessern und das Portfolio des Unternehmens zu nutzen. Das Führungsteam hat sich zum Ziel gesetzt, das Wachstum und die Rentabilität zu beschleunigen, während es sich auf die Erfahrungen von Patienten und Anbietern konzentriert.
- Eight consecutive quarters of double-digit revenue growth in Clinical division
- Strategic alignment of commercial and operations teams under unified leadership
- Promotion from within indicates strong internal succession planning
- Departure of current Chief Operations Officer could cause temporary operational disruption
Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities
Leadership team aligned to support long term growth, profitability, and operational execution
Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible for driving the Company’s lab operations, data solutions division and enterprise operations functions, while maintaining his overall existing commercial responsibilities – including clinical, pharma, marketing and product management functions, and customer service initiatives. Melody Harris, the Company’s current Chief Operations Officer, will depart NeoGenomics at the end of May.
“Since joining NeoGenomics in November 2022, Warren has played an integral role in shaping the Company’s long-term growth strategy by instilling rigor and accountability throughout our commercial organization and advanced our critical business initiatives. This has resulted in eight consecutive quarters of double-digit revenue growth for the Clinical division and affirmed a leadership position in the cancer marketplace,” said Chris Smith, CEO of NeoGenomics. “We are grateful to Melody for her many contributions to NeoGenomics and wish her the very best in her next endeavor.”
“I am excited to continue working closely with Warren in his new role. The alignment of our commercial and operations teams increases agility and enables us to further leverage our portfolio and the selling channel, as we focus on driving innovation through research & development and business development opportunities,” said Tony Zook, incoming CEO. “We have a strong leadership team in place with diverse and complementary skills and experience. Together, we look forward to accelerating our strategy to drive growth and profitability in line with our long-range plan while focusing on delivering an exceptional experience for patients and providers.”
Beth Eastland, NeoGenomics’ Senior Vice President, Enterprise Sales, will support Mr. Stone in his new role and assume day-to-day responsibility for all enterprise sales functions. Prior to joining NeoGenomics in 2024, Ms. Eastland was employed by a leading oncology diagnostics provider and has over 35 years of commercial experience in healthcare.
About Warren Stone
Mr. Stone has been with NeoGenomics since November 2022. He joined as President, Clinical Services, and was promoted to Chief Commercial Officer in April 2024. In this capacity, he was responsible for overall strategy for the commercial organization, including clinical and pharma services. Prior to NeoGenomics, he was President,
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in
Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250318775290/en/
Investor Contact
Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
Source: NeoGenomics, Inc.
FAQ
When will Warren Stone assume the role of President & COO at NeoGenomics (NEO)?
What has been NeoGenomics (NEO) Clinical division's performance under Warren Stone's leadership?
What will be Warren Stone's responsibilities as NEO's new President & COO?
How will the leadership restructuring impact NeoGenomics (NEO) operations?
